Market Overview

UPDATE: Credit Suisse Reiterates Outperform Rating, Lowers PT on Teva Pharmaceutical Industries

Share:
Related TEVA
Benzinga's M&A Chatter for Wednesday April 22, 2015
Analyst Finds Perrigo 'Still Attractive' As Take Out Target
Teva Puts Forth Its Best Bid To Acquire Mylan (GuruFocus)

In a report published Monday, Credit Suisse Group reiterated its Outperform rating on Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), but slightly lowered its price target from $51.00 to $50.00.

Credit Suisse noted, “We would be buyers of Teva shares ahead of the Dec. 11th investor day. Teva's 2013 guidance of $4.85-$5.15 was well below consensus and our expectations; however, our overall impression from the co.'s call was positive. Teva has set a new, makeable bar for 2013, and has shown increased transparency in its guidance. The co.'s 2013 guidance dispenses with the market's apprehension about "how low" the numbers would be, and allows the company to focus investor attention at the Dec. 11th event on several more positive, long-term topics: (1) portfolio strategy (including business development and pipeline details); (2) capital allocation; and (3) details on the newly announced $1.5 - $2.0 Bn cost cut program.”

Teva Pharmaceutical Industries Ltd. closed on Friday at $40.35.

Latest Ratings for TEVA

DateFirmActionFromTo
Apr 2015Argus ResearchMaintainsBuy
Apr 2015BMO CapitalDowngradesOutperformMarket Perform
Apr 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Credit Suisse GroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (TEVA)

Around the Web, We're Loving...